Nuage Tx wins Best Poster Award at the 12th Novalix Conference on Biophysics in Drug Discovery (BiDD)

The poster Biophysics-Enabled Discovery of Small Molecule Ligands for the Druggable States of the Intrinsically Disordered Oncogenic Driver ASCL1, was recognised for showcasing the critical role of biophysics in advancing drug discovery.

The work, presented by our CTO Mateusz Biesaga, highlights how Nuage Tx’s unique proprietary platform enables the study of intrinsically disordered proteins (IDPs) when they transiently adopt higher-order conformations. Our cutting-edge platform enables access to these states, allowing the design of compounds that can bind and inhibit this class of proteins, traditionally considered undruggable.

This approach represents a paradigm shift in drug discovery, transforming protein disorder – traditionally seen as a limitation – into a therapeutic opportunity for cancer treatment. The results reinforce that IDPs can be drugged when probed with the right tools. 

At Nuage Tx, we remain committed to pushing the boundaries of what’s possible. We continue advancing our mission to develop a new generation of precision therapies for aggressive cancers with limited treatment options. Beyond oncology, our ambition is to become the leading company in the field of Intrinsically Disordered Proteins (IDPs), extending the use of this technology to therapeutic areas in which protein disorder plays a key role and treatment options remain scarce.